A recently announced six-member consortium of pharmaceutical companies is planning to turn the UK Biobank into the world’s largest publicly accessible concentration of genetic and health data. The effort is being led by Regeneron, which will perform the work at its Tarrytown, NY facility, one of the world’s largest and most sophisticated human genetics sequencing...
Developing an Alzheimer’s disease drug has been notoriously expensive and high risk. Part of the problem has been the difficulty in identifying the right patients for clinical trials and at the right time – that is, those patients showing early signs of cognitive impairment who will progress to AD. However, new diagnostics, biomarkers, and digital...
Depression is a difficult problem for drug developers. Current marketed antidepressants are effective for a relatively small percentage of patients (about 20 in 100) and most require weeks of treatment to show an effect. Patients often need to try several drugs to find one that works for them, and some patients do not respond to...
Now that the holidays have wound down, we look forward to catching up with many of you in person as the Bionest team and many others from across the healthcare business world descend on San Francisco next week for the three-ring circus of conferences, one-on-one meetings and social gatherings that is JPM18. Here are some...